BioAegis Therapeutics Awarded $20 Million BARDA DRIVe : comp

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for...

Related Keywords

Steven Cordovano , Christine Lagana , Susan Levinson , Division Of Research , Us Department Of Health , Bioaegis Therapeutics Inc , Development Authority , Administration For Strategic Preparedness , Biomedical Advanced Research , Society Vulnerability To Global Pandemics , Human Services , Aegis Therapeutics , Strategic Preparedness , Acute Respiratory Distress Syndrome , Reduce Society , Respiratory Distress Syndrome , Multitasking Protein , Complex Condition , Chief Executive Officer , Bioaegis Therapeutics , Cards , Pneumonia , Sepsis , Lrp3 Inflammasome , Inflammation , Harda , Innate Immune System , Elsolin , Biotech Investing , Mr , Immunotherapy , L 1b ,